Aligos Therapeutics, Inc.

US$4.07As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ALGSHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (52.79%)
Div yield —
ROE (159.46%)
Biotechnology
Beta (5Y) 2.43
PE TTM —
TSR TTM (50.67%)
Mkt cap US$25.42M
ROIC (89.66%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.05
(0.47%)
(37.38%)
Hold 11|0|8|7|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.07
0.06
0.06
0.06
(0.31%)
(5.79%)
(6.84%)
(13.68%)
Revenue$M
1.502
1.461
1.491
1.499
3.97%
(2.47%)
(3.00%)
(0.90%)
Peers (US$25.42M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.394
0.054
0.056
EBIT/Intx
0.469
0.125
0.124
Own earn%
(91.53)
(57.92)
(53.05)
Sh yield%
43.83
45.85
45.96
Owners
Insiders/Inst%
4.46
78.15
Short interest%
0.52
SBC / revenue%
5.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
20–25
$1 testx
—
Incr. ROIC%
9